About Careers Internship MedBlog Contact us

Canada Bans Sale of Painkiller Prexige of Novartis

by Medindia Content Team on October 5, 2007 at 5:44 PM
Canada Bans Sale of Painkiller Prexige of Novartis

Health Canada stopped the sale of Novartis's anti-inflammatory drug Prexige Thursday and revoked its market authorization in this country because it may cause "serious" liver damage, the ministry said.

Prexige, a non-steroidal anti-inflammatory drug, has been marketed in Canada since November 2006 for the treatment of osteoarthritis symptoms in adults at a maximum daily dose of 100 milligrams (mg).


"The decision to withdraw market authorization for Prexige follows a review of additional safety information submitted by the drug manufacturer," Health Canada said in a statement.

It asked Swiss giant Novartis Pharmaceuticals for the data after Prexige was removed from the Australian market in August, following reports of "serious liver adverse events" linked to the drug at doses of 200 mg and 400 mg daily.

"As a result of its review, Health Canada has concluded that the risk of serious liver-related adverse events with Prexige cannot be safely and effectively managed at the 100 mg daily dose," the ministry said.

There have been four cases internationally, including two in Canada, of hepatitis associated with the use of Prexige at the 100 mg dose, it said.

In a statement, Novartis urged patients in Canada to "stop taking this treatment immediately and contact their doctor to seek advice on other treatment options," in compliance with Health Canada's decision.

The drug manufacturer, however, noted there were "no cases of jaundice or hepatic failure" in clinical trials of Prexige at 100 mg once-daily dosing.

As well, only 0.85 percent of patients had elevations of the liver enzymes aspartate aminotransferase and alanine aminotransferase -- liver damage markers -- similar to levels observed with other currently available non-steroidal anti-inflammatory drugs, Novartis said.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Painkillers With Hormonal Contraception Linked to Blood Clot Risk
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
Finger Sweat Test Enables Antipsychotic Drug Detection
The recently created assay identifies antipsychotic drugs present in sweat.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Canada Bans Sale of Painkiller Prexige of Novartis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests